Eli Lilly has filed six lawsuits against U.S. entities it accuses of illegally selling versions of its experimental obesity drug retatrutide. The lawsuits target compounding pharmacies, medical spas and online sellers that allegedly sold retatrutide products, according to an Aug.…
GLP-1s
New research is reshaping how clinicians think about GLP-1 use across pregnancy and obesity care, alongside major legal and financial developments for the drugs’ top manufacturers. Here are eight GLP-1 updates to know.
A federal judge has dismissed an antitrust lawsuit brought by compounding pharmacy Strive Specialties against Eli Lilly and Novo Nordisk. The ruling, filed Aug. 3 in the U.S. District Court for the Western District of Texas, found the company failed…
This fall, CMS will start sharing monthly utilization reports with Part D plans on how their enrollees are using the Medicare GLP-1 Bridge program. The agency said in an Aug. 5 memo that the reports will be organized at both…
Eli Lilly and Co. extended its advantage over Novo Nordisk in the GLP-1 market during the second quarter, even as Novo’s oral Wegovy notched a strong early launch. Lilly reported Aug. 5 second-quarter revenue of $22.97 billion, up 48% year…
Advertisement
An international panel of experts has published a systematic review and consensus guidelines on the use of incretin-based medications in women’s reproductive health, offering hospitals and clinicians recommendations for counseling patients before, during and after pregnancy, according to research published…
CVS Health has revamped its direct-to-consumer weight management program to expand access to GLP-1 medications. The company lowered the cost of MinuteClinic online weight loss visits to $29, down from $49 at launch in June, with no recurring membership or…
As employers scale back coverage for GLP-1 weight-loss drugs, major retailers and pharmacy chains are expanding direct-to-consumer prescription programs to capture patients shifting to cash-pay options. Walmart, Costco, Amazon and CVS are investing in programs that combine GLP-1 prescriptions with…
Eli Lilly has built a formal expanded access program for retatrutide, its experimental obesity drug, following weeks of physician inquiries about securing the same early access previously granted to a single patient. “For a limited number of patients who meet…
GLP-1 therapies may allow clinicians to tailor obesity treatment to patients’ individual cardiometabolic needs rather than focusing on weight loss alone, according to a July 27 analysis published in the journal Diabetes, Obesity, and Metabolism. Researchers from the Perelman School…